Shattuck Labs Inc (STTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shattuck Labs Inc (STTK) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.93 Million) by net assets ($93.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shattuck Labs Inc net asset quality index to measure how much of total assets are equity-financed.
Shattuck Labs Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Shattuck Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Shattuck Labs Inc to evaluate the quality of earnings relative to operating cash generation.
Shattuck Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shattuck Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sino AG
F:XTP
|
N/A |
|
Jiangsu Smartwin Electronics Technology Co.Ltd.
SHE:301106
|
N/A |
|
Genfit S.A.
NASDAQ:GNFT
|
-0.574x |
|
GDI Property Group
AU:GDI
|
0.019x |
|
Pihlajalinna Oy
HE:PIHLIS
|
0.091x |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
0.046x |
|
Evgo Inc
NASDAQ:EVGO
|
-0.100x |
|
W&T Offshore Inc
NYSE:WTI
|
-0.154x |
Annual Cash Flow Conversion Efficiency for Shattuck Labs Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Shattuck Labs Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Shattuck Labs Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $79.63 Million | $-60.52 Million | -0.760x | -35.39% |
| 2023-12-31 | $144.71 Million | $-81.23 Million | -0.561x | -4.64% |
| 2022-12-31 | $176.16 Million | $-94.50 Million | -0.536x | -155.27% |
| 2021-12-31 | $271.79 Million | $-57.12 Million | -0.210x | -93.46% |
| 2020-12-31 | $309.86 Million | $-33.66 Million | -0.109x | -117.89% |
| 2019-12-31 | $-34.55 Million | $-20.98 Million | 0.607x | -2.54% |
| 2018-12-31 | $-11.08 Million | $-6.90 Million | 0.623x | -- |
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more